Six diagnostic kits have been commercialized at national and international markets and more are in the pipeline. Rapid diagnostics commercialized include antibody detection to Salmonella Typhi using dot EIA via TYPHIDOT (to detect for specific lgM and lgG), TYPHIDOT-M (to detect for
specific lgM), TYPHirapid (a immunochromatography test for rapid detection of lgM to Salmonella Typhi), Brugia Rapid to detect brugian filariasis caused by Brugia malayi and Brugia timori and panLF Rapid to detect both brugian and bancroftian filariasis. The latest innovations are diagnostic kits that do not require "cold chain transport", thus making important diagnostics available and accessible in many low resource countries. The inventions of INFORMM are patented and resultant diagnostic kits of INFORMM are licensed to commercial partners who take over the marketing and support for the products. Commercialization is important to enable these kits be made available to the end users for diagnosis, while income generation from the commercial activities are important for the sustainability of research activities and product.
List of products:
- TYPHIrapid - Discontinued
- WBrapidTM - Discontinued